 NEW YORK and LONDON, June 29, 2021 GLOBE NEWSWIRE -- Akari Therapeutics, Plc Nasdaq: AKTX, a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement C5 andor leukotriene LTB4 systems are implicated, today announced financial results for the first quarter of 2021, as well as recent clinical progress. 